BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

FDA Approves Cu-64 SAR-bisPSMA Phase III Trial for Prostate Cancer

FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer Phase III trial design based on&n...

July 05, 2023 | News

Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China

The pivotal clinical trial approved in China will evaluate the efficacy and safety of Glecirasib as a single agent for the second line treatment ...

July 05, 2023 | News

Innovent and IASO Bio Receive NMPA Approval for FUCASO®, a Fully-human BCMA CAR-T Therapy for Multiple Myeloma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

July 03, 2023 | News

Thermo Fisher Scientific Introduces Tumor Culture Medium for Faster Cancer Treatment Development

Thermo Fisher Scientific, a global leading company in science services, today announced the launch of the Gibco™ OncoPro™ tumor media kit. *, t...

June 29, 2023 | News

Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET™ technology

By using this cutting-edge imaging technology in preclinical studies, Oncodesign Services’ team hopes to gain insights of the predictive effectivenes...

June 29, 2023 | News

INOVIQ's SubB2M/CA15-3 Breast Cancer Test Shows Excellent Clinical Data

INOVIQ's SubB2M/CA15-3 breast cancer test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) The...

June 28, 2023 | News

CStone Receives China NMPA Approval for GAVRETO® in First-Line Treatment of RET Fusion-Positive Lung Cancer.

The approval for the first-line treatment of RET fusion-positive non-small cell lung cancer marks the third indication of GAVRETO in Mainland Chi...

June 27, 2023 | News

Prenetics and Prof. Dennis Lo Launch US$200m Joint Venture "Insighta" for Multi-Cancer Early Detection

- Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostics w...

June 26, 2023 | News

Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharmaceuticals to Develop a Novel Cancer Therapeutic

The Lubrizol Corporation announces the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton). The licen...

June 23, 2023 | News

Telix to Present ZIRCON Phase III Kidney Cancer Imaging Data at SNMMI

Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (Clinic...

June 23, 2023 | News

SeekIn paves the way for cancer early detection in low- and middle-income countries

The overall accuracy of TOO prediction in the true positives is 66.8%, which may be supportive in the clinical diagnostic workup. OncoSeek® ...

June 19, 2023 | News

FDA Approves Phase I/II Trial for Leads Biolabs' Anti-MUC16/CD3 Bispecific Antibody in Advanced Solid Tumors.

The study is a multicenter, open-label, dose-escalation and expansion phase Ⅰ/Ⅱ clinical study. The phase Ⅰ part aims to evaluate the safety, to...

June 19, 2023 | News

FDA Approves Utidelone Injectable (UTD1) Trial for Non-Small Cell Lung Cancer

Designated as BG01-2202, this trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable (UTD1) v...

June 16, 2023 | News

NCCN Unveils Thyroid Cancer Care Roadmap for Low- and Middle-Income Countries on Global Stage

The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-inco...

June 15, 2023 | News

Stay Connected